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Introduction
Serious infections are a major concern in JIA patients
treated with immunosuppressants and biologics. Effect
of TNF inhibitors on the risk for serious infections and
further factors are studied here.
Methods
Pts exposed to Etanercept (ETA), Adalimumab (ADA) and
Methotrexate (MTX) but no biologics and serious infec-
tions were identified in the BIKER registry. Descriptive sta-
tistics, infection rates, Cox-regression, Hazard ratios (HR)
were calculated. Potential risk factors were analysed.
Results
A total of 3350 pts. with 5929 exposure years were iden-
tified in the German BIKER registry data base. First bio-
logic was ETA in 1720 and ADA in 177 cases. 1353
patients were not exposed to biologics. 28 serious infec-
tions have been reported (4.7/1000 pt-years). MTX
patients had 5 events, Etanercept patients 21 and
patients with Adalimumab therapy 2 events.The serious
infections were of bacterial origin in 16, viral in 10 and
unknown in 2. Total infection incidence per 1000 person
years was 4.72 (CI 3.26 – 6.84). The highest rate was
found under ADA (9.73, CI 2.43-38.91) followed by
ETA (8.08, CI 5.27 – 12.40) and the lowest rate of 1.6
(CI 0.67 – 3.84) with MTX. Univariate Cox regression
revealed a number of significant risks for infection,
beside therapy (p=0.004) also JADAS10 at start of ther-
apy, mean JADAS level during therapy, corticosteroids
as pre- or concomitant medication as well as MTX and
DMARDS as premedication were relevant. In multivari-
ate Cox regression only therapy and mean JADAS10
during observation time remained significant. Both ETA
(HR=4.88) and ADA (HR=10.06) showed an increased
risk compared to MTX, whereas ADA and ETA differed
not significally. Risk for infection was significantly
increased by an elevated mean JADAS10 level
(HR=1.12). Gender, JIA category, age at start of disease,
disease duration, ANA status were not significant.
Kaplan Meier analysis confirmed the influence of disease
activity as demonstrated by the JADAS10. Table 1.
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Table 1
Variable univariate HR (CI) multivarite HR (CI)
ADA / MTX p=0.022 7.28(1.32-40.04) p00.019 10.06(1.67-60.67)
ETA / MTX p=0.001 5.96 (2.03-17.48) p=0.013 4.88(1.39-17.08)
More than 1 DMARD failure p=0.006 3.06 (1.39-6.75)
Pretreatment with steroids p=0.007 3.02(1.34-6.77)
Steroids at baseline p=0.026 0.418 (0.19-0.90)
MTX concomitant p=0.001 5.54(2.08-14.71)
JADAS baseline p=0.004 1.09 (1.03-1.16)
Mean JADAS-level p<0.001 1.12(1.05-1.19) p<0.001 1.12(1.05-1.19)
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Conclusion
ETA and ADA treatment as well as higher disease activity
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